Macrolide Drugs Market by Drug Type and Distribution Channel - Global Industry Analysis and Forecast To 2023

2018-05-30 / 3800.00 / Pharma & Healthcare / 104 Pages

Description

Industry Outlook and Trend Analysis

The global Macrolide Drug market was worth USD 24.65 billion in the year 2014 and is expected to reach approximately USD 70.88 billion by 2023, while registering itself at a compound annual growth rate (CAGR) of 12.45% during the forecast period. Macrolides is a class of antibacterial medications that contain a vast macrocyclic lactone ring substituted with certain bizarre sugars. This class involves drugs that repress protein combination in unsafe and irresistible gram-positive microscopic organisms. These particles tie to the 50S ribosomal unit, in this manner confining the ribosomes from doing the bacterial protein amalgamation. Protein amalgamation in microscopic organisms is restrained by macrolide drugs. Macrolide drugs are fundamentally bacteriostatic; be that as it may, they might be bactericidal at high fixations or relying upon the sort of bacterial strain. These medications were first separated from Streptomyces erythraeus. The medication was named erythromycin back in the 1950s. Two other manufactured subsidiaries viz. clarithromycin and azithromycin were later created by using erythromycin in the 1980s individually.



Drug Type Outlook and Trend Analysis

On the basis of Drug Type, the global Macrolide Drugs market is segmented into erythromycin, clarithromycin, azithromycin, dirithromycin, roxithromycin, troleandomycin, fidaxomicin, and telithromycin. Macrolides have a wide range of action and are viable against a few bacterial strains of Streptococcus, Clostridium, Corynebacterium, Haemophilus, Listeria, Legionella, Staphylococcus, Mycoplasma sp. and Neisseria meningitidis. Macrolide drugs are dynamic against gram-positive microorganisms, as they can without much of a stretch infiltrate the cell dividers of gram-positive microscopic organisms. Neither peptidoglycan (show in bacterial cell dividers) nor the cytoplasmic film goes about as an obstruction to these atoms when they enter the cell dividers of gram-positive microscopic organisms.

Distribution Channel Outlook and Trend Analysis

On the basis of Distribution Channel, the global Macrolide Drugs market is segmented into hospital pharmacies, clinics, hospitals, retail pharmacies, and online pharmacies. The worldwide macrolide drugs showcase is expected to grow at a direct rate amid the estimate time frame. Key development drivers for the market incorporate the expanding predominance of irresistible maladies, developing elderly populace, expanding number of multidrug-safe bacterial strains, and higher advantages over conventional anti-infection agents. Most created economies, for example, the U.S., Japan, and nations of Western Europe have huge elderly population that is more inclined to different bacterial diseases fundamentally caused by low invulnerability.

Regional Outlook and Trend Analysis

Increasing prevalence of bacterial contamination and expanding government activities that seem, by all accounts, to be advancing toward shorter times of patent selectiveness for new medication applications are a portion of the elements driving the market in these locales. In addition, substantial populace, expanding extra cash, and developing patient mindfulness are a portion of alternate components driving the market in Asia Pacific. Europe and Rest of the World are probably going to exhibit noteworthy development openings in the macrolide drugs showcase. This is owing to expanding geriatric population in these districts, which is more inclined to bacterial contaminations activated by low insusceptibility.

Competitive Insights

The key players of global macrolide drugs market report incorporate Eli Lilly & Co., Pfizer, Inc., Sanofi, Merck & Co., Inc., Abbott Laboratories, and Akorn, Inc.

The Macrolide Drugs Market is segmented as follows-

By Drug Type:


Erythromycin
Clarithromycin
Azithromycin
Dirithromycin
Roxithromycin
Troleandomycin
Fidaxomicin
Telithromycin


By Distribution Channel:


Hospital Pharmacies
Clinics
Hospitals
Retail Pharmacies
Online Pharmacies


By Region


North America



U.S
Canada
Mexico



Europe



Germany
France
UK
Italy
Spain
Rest of Europe



Asia-Pacific



Japan
China
Australia
India
South Korea
Rest of Asia Pacific



Rest of the World



Brazil
South Africa
Saudi Arabia
United Arab Emirates
Others


Some of the key questions answered by the report are:


What was the market size in 2014 and forecast from 2014 to 2023`
What will be the industry market growth from 2014 to 2023`
What are the major drivers, restraints, opportunities, challenges and industry trends and their impact on the market forecast`
What are the major segments leading the market growth and why`
Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition`

Table of Content

Table of Contents

1. Introduction

1.1. Report Description

1.2. Research Methodology

1.2.1. Secondary Research

1.2.2. Primary Research

2. Executive Summary

2.1. Key Highlights

3. Market Overview

3.1. Introduction

3.1.1. Market Definition

3.1.2. Market Segmentation

3.2. Market Dynamics

3.2.1. Drivers

3.2.2. Restraints

3.2.3. Opportunities

4. Macrolide Drugs Market, By Drug Type

4.1. Introduction

4.2. Macrolide Drugs Market Assessment and Forecast, By Drug Type, 2014-2023

4.3. Erythromycin

4.3.1. Market Assessment and Forecast, By Region, 2014-2023 ($Million)

4.4. Clarithromycin

4.4.1. Market Assessment and Forecast, By Region, 2014-2023 ($Million)

4.5. Roxithromycin

4.5.1. Market Assessment and Forecast, By Region, 2014-2023 ($Million)

4.6. Troleandomycin

4.6.1. Market Assessment and Forecast, By Region, 2014-2023 ($Million)

4.7. Fidaxomicin

4.7.1. Market Assessment and Forecast, By Region, 2014-2023 ($Million)

4.8. Azithromycin

4.8.1. Market Assessment and Forecast, By Region, 2014-2023 ($Million)

4.9. Dirithromycin

4.9.1. Market Assessment and Forecast, By Region, 2014-2023 ($Million)

4.10. Telithromycin

4.10.1. Market Assessment and Forecast, By Region, 2014-2023 ($Million)

5. Macrolide Drugs Market, By Distribution Channel

5.1. Introduction

5.2. The Macrolide Drugs Market Assessment and Forecast, By Distribution Channel, 2014-2023

5.3. Hospital pharmacies

5.3.1. Market Assessment and Forecast, By Region, 2014-2023 ($Million)

5.4. Clinics

5.4.1. Market Assessment and Forecast, By Region, 2014-2023 ($Million)

5.5. Hospitals

5.5.1. Market Assessment and Forecast, By Region, 2014-2023 ($Million)

5.6. Retail pharmacies

5.6.1. Market Assessment and Forecast, By Region, 2014-2023 ($Million)

5.7. Online pharmacies

5.7.1. Market Assessment and Forecast, By Region, 2014-2023 ($Million)

6. Macrolide Drugs Market, By Region

6.1. Introduction

6.2. Macrolide Drugs Market Assessment and Forecast, By Region, 2014-2023 ($Million)

6.3. North America

6.3.1. Market Assessment and Forecast, By Country, 2014-2023 ($Million)

6.3.2. Market Assessment and Forecast, By Drug Type, 2014-2023 ($Million)

6.3.3. Market Assessment and Forecast, By Distribution Channel, 2014-2023 ($Million)

6.3.4. U.S.

6.3.4.1. Market Assessment and Forecast, By Drug Type, 2014-2023 ($Million)

6.3.4.2. Market Assessment and Forecast, By Distribution Channel, 2014-2023 ($Million)

6.3.5. Canada

6.3.5.1. Market Assessment and Forecast, By Drug Type, 2014-2023 ($Million)

6.3.5.2. Market Assessment and Forecast, By Distribution Channel, 2014-2023 ($Million)

6.3.6. Mexico

6.3.6.1. Market Assessment and Forecast, By Drug Type, 2014-2023 ($Million)

6.3.6.2. Market Assessment and Forecast, By Distribution Channel, 2014-2023 ($Million)

6.4. Europe

6.4.1. Market Assessment and Forecast, By Country, 2014-2023 ($Million)

6.4.2. Market Assessment and Forecast, By Drug Type, 2014-2023 ($Million)

6.4.3. Market Assessment and Forecast, By Distribution Channel, 2014-2023 ($Million)

6.4.4. Germany

6.4.4.1. Market Assessment and Forecast, By Drug Type, 2014-2023 ($Million)

6.4.4.2. Market Assessment and Forecast, By Distribution Channel, 2014-2023 ($Million)

6.4.5. France

6.4.5.1. Market Assessment and Forecast, By Drug Type, 2014-2023 ($Million)

6.4.5.2. Market Assessment and Forecast, By Drug Type, 2014-2023 ($Million)

6.4.6. UK

6.4.6.1. Market Assessment and Forecast, By Drug Type, 2014-2023 ($Million)

6.4.6.2. Market Assessment and Forecast, By Distribution Channel, 2014-2023 ($Million)

6.4.7. Italy

6.4.7.1. Market Assessment and Forecast, By Drug Type, 2014-2023 ($Million)

6.4.7.2. Market Assessment and Forecast, By Distribution Channel, 2014-2023 ($Million)

6.4.8. Spain

6.4.8.1. Market Assessment and Forecast, By Drug Type, 2014-2023 ($Million)

6.4.8.2. Market Assessment and Forecast, By Distribution Channel, 2014-2023 ($Million)

6.4.9. Rest of Europe

6.4.9.1. Market Assessment and Forecast, By Drug Type, 2014-2023 ($Million)

6.4.9.2. Market Assessment and Forecast, By Distribution Channel, 2014-2023 ($Million)

6.5. Asia-Pacific

6.5.1. Market Assessment and Forecast, By Country, 2014-2023 ($Million)

6.5.2. Market Assessment and Forecast, By Drug Type, 2014-2023 ($Million)

6.5.3. Market Assessment and Forecast, By Distribution Channel, 2014-2023 ($Million)

6.5.4. Japan

6.5.4.1. Market Assessment and Forecast, By Drug Type, 2014-2023 ($Million)

6.5.4.2. Market Assessment and Forecast, By Distribution Channel, 2014-2023 ($Million)

6.5.5. China

6.5.5.1. Market Assessment and Forecast, By Drug Type, 2014-2023 ($Million)

6.5.5.2. Market Assessment and Forecast, By Distribution Channel, 2014-2023 ($Million)

6.5.6. Australia

6.5.6.1. Market Assessment and Forecast, By Drug Type, 2014-2023 ($Million)

6.5.6.2. Market Assessment and Forecast, By Distribution Channel, 2014-2023 ($Million)

6.5.7. India

6.5.7.1. Market Assessment and Forecast, By Drug Type, 2014-2023 ($Million)

6.5.7.2. Market Assessment and Forecast, By Distribution Channel, 2014-2023 ($Million)

6.5.8. South Korea

6.5.8.1. Market Assessment and Forecast, By Drug Type, 2014-2023 ($Million)

6.5.8.2. Market Assessment and Forecast, By Distribution Channel, 2014-2023 ($Million)

6.5.9. Rest of Asia-Pacific

6.5.9.1. Market Assessment and Forecast, By Drug Type, 2014-2023 ($Million)

6.5.9.2. Market Assessment and Forecast, By Distribution Channel, 2014-2023 ($Million)

6.6. Rest of the World

6.6.1. Market Assessment and Forecast, By Country, 2014-2023 ($Million)

6.6.2. Market Assessment and Forecast, By Drug Type, 2014-2023 ($Million)

6.6.3. Market Assessment and Forecast, By Distribution Channel, 2014-2023 ($Million)

6.6.4. Brazil

6.6.4.1. Market Assessment and Forecast, By Drug Type, 2014-2023 ($Million)

6.6.4.2. Market Assessment and Forecast, By Distribution Channel, 2014-2023 ($Million)

6.6.5. Turkey

6.6.5.1. Market Assessment and Forecast, By Drug Type, 2014-2023 ($Million)

6.6.5.2. Market Assessment and Forecast, By Distribution Channel, 2014-2023 ($Million)

6.6.6. Saudi Arabia

6.6.6.1. Market Assessment and Forecast, By Drug Type, 2014-2023 ($Million)

6.6.6.2. Market Assessment and Forecast, By Distribution Channel, 2014-2023 ($Million)

6.6.7. South Africa

6.6.7.1. Market Assessment and Forecast, By Drug Type, 2014-2023 ($Million)

6.6.7.2. Market Assessment and Forecast, By Distribution Channel, 2014-2023 ($Million)

6.6.8. United Arab Emirates

6.6.8.1. Market Assessment and Forecast, By Drug Type, 2014-2023 ($Million)

6.6.8.2. Market Assessment and Forecast, By Distribution Channel, 2014-2023 ($Million)

6.6.9. Others

6.6.9.1. Market Assessment and Forecast, By Drug Type, 2014-2023 ($Million)

6.6.9.2. Market Assessment and Forecast, By Distribution Channel, 2014-2023 ($Million)

7. Company Profiles

7.1. Eli Lilly & Co.

7.1.1. Business Overview

7.1.2. Product Portfolio

7.1.3. Key Financials

7.1.4. Strategic Developments

7.2. Pfizer, Inc.

7.2.1. Business Overview

7.2.2. Product Portfolio

7.2.3. Strategic Developments

7.3. Sanofi

7.3.1. Business Overview

7.3.2. Product Portfolio

7.3.3. Key Financials

7.3.4. Strategic Developments

7.4. Merck & Co., Inc.

7.4.1. Business Overview

7.4.2. Product Portfolio

7.4.3. Strategic Developments

7.5. Abbott Laboratories

7.5.1. Business Overview

7.5.2. Product Portfolio

7.5.3. Key Financials

7.5.4. Strategic Developments

7.6. Akorn, Inc.

7.6.1. Business Overview

7.6.2. Product Portfolio

7.6.3. Strategic Developments

7.7. Sandoz International GmbH

7.7.1. Business Overview

7.7.2. Product Portfolio

7.7.3. Strategic Developments

7.8. WOCKHARDT

7.8.1. Business Overview

7.8.2. Product Portfolio

7.8.3. Key Financials

7.8.4. Strategic Developments


Table of Figures

Table 1.Global Macrolide Drugs Market, By Drug Type ($Million), 2014-2023

Table 2.Erythromycin Market, By Region ($Million), 2014-2023

Table 3.Clarithromycin Market, By Region ($Million), 2014-2023

Table 4.Roxithromycin Market, By Region ($Million), 2014-2023

Table 5.Troleandomycin Market, By Region ($Million), 2014-2023

Table 6.Fidaxomicin Market, By Region ($Million), 2014-2023

Table 7.Azithromycin Market, By Region ($Million), 2014-2023

Table 8.Dirithromycin Market, By Region ($Million), 2014-2023

Table 9.Telithromycin Market, By Region ($Million), 2014-2023

Table 10.Global Macrolide Drugs Market, By Distribution Channel ($Million), 2014-2023

Table 11.Hospital pharmacies Market, By Region ($Million), 2014-2023

Table 12.Clinics Market, By Region ($Million), 2014-2023

Table 13.Hospitals Market, By Region ($Million), 2014-2023

Table 14.Retail pharmacies Market, By Region ($Million), 2014-2023

Table 15.Online pharmacies Market, By Region ($Million), 2014-2023

Table 16.North America Macrolide Drugs Market, By Country, 2014-2023 ($Million)

Table 17.North America Macrolide Drugs Market, By Drug Type, 2014-2023 ($Million)

Table 18.North America Macrolide Drugs Market, By Distribution Channel, 2014-2023 ($Million)

Table 19.U.S. Macrolide Drugs Market, By Drug Type, 2014-2023 ($Million)

Table 20.U.S. Macrolide Drugs Market, By Distribution Channel, 2014-2023 ($Million)

Table 21.Canada Macrolide Drugs Market, By Drug Type, 2014-2023 ($Million)

Table 22.Canada Macrolide Drugs Market, By Distribution Channel, 2014-2023 ($Million)

Table 23.Mexico Macrolide Drugs Market, By Drug Type, 2014-2023 ($Million)

Table 24.Mexico Macrolide Drugs Market, By Distribution Channel, 2014-2023 ($Million)

Table 25.Europe Macrolide Drugs Market, By Country, 2014-2023 ($Million)

Table 26.Europe Macrolide Drugs Market, By Drug Type, 2014-2023 ($Million)

Table 27.Europe Macrolide Drugs Market, By Distribution Channel, 2014-2023 ($Million)

Table 28.Germany Macrolide Drugs Market, By Drug Type, 2014-2023 ($Million)

Table 29.Germany Macrolide Drugs Market, By Distribution Channel, 2014-2023 ($Million)

Table 30.France Macrolide Drugs Market, By Drug Type, 2014-2023 ($Million)

Table 27.France Macrolide Drugs Market, By Distribution Channel, 2014-2023 ($Million)

Table 28.UK Macrolide Drugs Market, By Drug Type, 2014-2023 ($Million)

Table 29.UK Macrolide Drugs Market, By Distribution Channel, 2014-2023 ($Million)

Table 30.Italy Macrolide Drugs Market, By Drug Type, 2014-2023 ($Million)

Table 31.Italy Macrolide Drugs Market, By Distribution Channel, 2014-2023 ($Million)

Table 32.Spain Macrolide Drugs Market, By Drug Type, 2014-2023 ($Million)

Table 33.Spain Macrolide Drugs Market, By Distribution Channel, 2014-2023 ($Million)

Table 34.Rest of Europe Macrolide Drugs Market, By Drug Type, 2014-2023 ($Million)

Table 35.Rest of Europe Macrolide Drugs Market, By Distribution Channel, 2014-2023 ($Million)

Table 36.Asia-Pacific Macrolide Drugs Market, By Country, 2014-2023 ($Million)

Table 37.Asia-Pacific Macrolide Drugs Market, By Drug Type, 2014-2023 ($Million)

Table 38.Asia-Pacific Macrolide Drugs Market, By Distribution Channel, 2014-2023 ($Million)

Table 39.Japan Macrolide Drugs Market, By Drug Type, 2014-2023 ($Million)

Table 40.Japan Macrolide Drugs Market, By Distribution Channel, 2014-2023 ($Million)

Table 41.China Macrolide Drugs Market, By Drug Type, 2014-2023 ($Million)

Table 42.China Macrolide Drugs Market, By Distribution Channel, 2014-2023 ($Million)

Table 43.Australia Macrolide Drugs Market, By Drug Type, 2014-2023 ($Million)

Table 44.Australia Macrolide Drugs Market, By Distribution Channel, 2014-2023 ($Million)

Table 45.India Macrolide Drugs Market, By Drug Type, 2014-2023 ($Million)

Table 46.India Macrolide Drugs Market, By Distribution Channel, 2014-2023 ($Million)

Table 47.South Korea Macrolide Drugs Market, By Drug Type, 2014-2023 ($Million)

Table 48.South Korea Macrolide Drugs Market, By Distribution Channel, 2014-2023 ($Million)

Table 49.Rest of Asia-Pacific Macrolide Drugs Market, By Drug Type, 2014-2023 ($Million)

Table 50.Rest of Asia-Pacific Macrolide Drugs Market, By Distribution Channel, 2014-2023 ($Million)

Table 51.Rest of the World Macrolide Drugs Market, By Country, 2014-2023 ($Million)

Table 52.Rest of the World Macrolide Drugs Market, By Drug Type, 2014-2023 ($Million)

Table 53.Rest of the World Macrolide Drugs Market, By Distribution Channel, 2014-2023 ($Million)

Table 54.Brazil Macrolide Drugs Market, By Drug Type, 2014-2023 ($Million)

Table 55.Brazil Macrolide Drugs Market, By Distribution Channel, 2014-2023 ($Million)

Table 56.Turkey Macrolide Drugs Market, By Drug Type, 2014-2023 ($Million)

Table 57.Turkey Macrolide Drugs Market, By Distribution Channel, 2014-2023 ($Million)

Table 58.Saudi Arabia Macrolide Drugs Market, By Drug Type, 2014-2023 ($Million)

Table 59.Saudi Arabia Macrolide Drugs Market, By Distribution Channel, 2014-2023 ($Million)

Table 60.South Africa Macrolide Drugs Market, By Drug Type, 2014-2023 ($Million)

Table 61.South Africa Macrolide Drugs Market, By Distribution Channel, 2014-2023 ($Million)

Table 62.United Arab Emirates Macrolide Drugs Market, By Drug Type, 2014-2023 ($Million)

Table 63.United Arab Emirates Macrolide Drugs Market, By Distribution Channel, 2014-2023 ($Million)

Table 64.Others Macrolide Drugs Market, By Drug Type, 2014-2023 ($Million)

Table 65.Others Macrolide Drugs Market, By Distribution Channel, 2014-2023 ($Million)

Table 66.Eli Lilly & Co.: Key Strategic Developments, 2015-2017

Table 67.Pfizer, Inc.: Key Strategic Developments, 2015-2017

Table 68.Sanofi: Key Strategic Developments, 2015-2017

Table 69.Merck & Co., Inc.: Key Strategic Developments, 2015-2017

Table 70.Abbott Laboratories: Key Strategic Developments, 2015-2017

Table 71.Akorn, Inc.: Key Strategic Developments, 2015-2017

Table 72.Sandoz International GmbH: Key Strategic Developments, 2015-2017

Table 73.WOCKHARDT: Key Strategic Developments, 2015-2017

Request Sample

* mark fields are compulsory